A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin

Trial Profile

A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Gastrointestinal cancer; Lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms RADIANT-4
  • Sponsors Novartis; Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 Jan 2017 Results of subgroup analysis presented at the 2017 Gastrointestinal Cancers Symposium
    • 07 Dec 2016 Results of subgroup analysis (n=90; Nonfunctional Neuroendocrine Tumors (NET) of the Lung) presented at the 17th World Conference on Lung Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top